Leonardo Mirandola1, Yuefei Yu2, Martin J Cannon3, Marjorie R Jenkins4, Rakhshanda L Rahman5, Diane D Nguyen6, Fabio Grizzi7, Everardo Cobos8, Jose A Figueroa6, Maurizio Chiriva-Internati8. 1. Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA. 2. Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA. 3. University of Arkansas for Medical Sciences, Department of Obstetrics and Gynecology, Little Rock, AR, USA. 4. Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA. 5. Division of Surgical Oncology, Texas Tech University Medical Center, Amarillo, TX, USA. 6. Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Kiromic, Inc., Lubbock, TX, USA. 7. Humanitas Clinical and Research Center, Milano, Italy. 8. Department of Internal Medicine at the Division of Hematology & Oncology & Oncology, The Southwest Cancer Treatment and Research Center, Texas Tech University Health Sciences Center, Lubbock, TX, USA; Laura W Bush Institute for Women's Health and Center for Women's Health and Gender-Based Medicine, Amarillo, TX, USA; Kiromic, Inc., Lubbock, TX, USA.
Abstract
OBJECTIVE: Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. METHODS: We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. RESULT: We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. CONCLUSIONS: Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.
OBJECTIVE:Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. METHODS: We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancerpatients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. RESULT: We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. CONCLUSIONS: Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer.
Authors: Peter P Ruvolo; Vivian R Ruvolo; Jared K Burks; YiHua Qiu; Rui-Yu Wang; Elizabeth J Shpall; Leonardo Mirandola; Numsen Hail; Zhihong Zeng; Teresa McQueen; Naval Daver; Sean M Post; Maurizio Chiriva-Internati; Steven M Kornblau; Michael Andreeff Journal: Biochim Biophys Acta Mol Cell Res Date: 2018-04-12 Impact factor: 4.739
Authors: Jonas Elmwall; Jakub Kwiecinski; Manli Na; Abukar Ahmed Ali; Veronica Osla; Lindsey N Shaw; Wanzhong Wang; Karin Sävman; Elisabet Josefsson; Johan Bylund; Tao Jin; Amanda Welin; Anna Karlsson Journal: Infect Immun Date: 2017-06-20 Impact factor: 3.441